Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trial.

Landi, Antonio; Morici, Nuccia; Vranckx, Pascal; Frigoli, Enrico; Bonacchini, Luca; Omazzi, Barbara; Tresoldi, Moreno; Camponovo, Claudio; Moccetti, Tiziano; Windecker, Stephan; Valgimigli, Marco (2024). Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trial. Journal of cardiovascular medicine, 25(7), pp. 565-568. Italian Federation of Cardiology 10.2459/JCM.0000000000001639

Text edoxaban_and_or_colchicine_for_patients_with.215.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (722kB)

The optimal pharmacological management of patients with Coronavirus disease 2019 (COVID-19) managed outside the hospital remains largely unsettled. In the investigator-initiated, open-label CONVINCE trial, 59 outpatients with COVID-19 were randomized (2 × 2 factorial design) to colchicine versus no treatment (anti-inflammatory comparison) or edoxaban versus no treatment (anticoagulation comparison). The study had two co-primary outcomes (one for each randomization): major vascular thrombotic events (MVTE, the composite of asymptomatic proximal deep vein thrombosis [DVT], symptomatic proximal or distal DVT, symptomatic pulmonary embolism or thrombosis, myocardial infarction, ischemic stroke, non-central nervous system embolism and death) at 25 ± 3 days for the anticoagulation comparison and the composite of SARS-CoV-2 detection rates or freedom from death or hospitalizations at 14 ± 3 days for the anti-inflammatory comparison. The trial was prematurely halted due to slow recruitment and availability of effective vaccines. Overall, 16 patients were randomized to edoxaban plus colchicine, 13 to edoxaban, 14 to colchicine and 16 to standard of care. The study showed no significant difference in the two co-primary outcomes with edoxaban and/or colchicine versus standard of care. However, these results should be interpreted in light of the low-risk profile of included patients and the premature termination of the trial.

Interest & Impact

Downloads

1 since deposited on 30 May 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item